{"id":"NCT05458011","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study With an Open-Label Treatment Period of Fremanezumab Administered Subcutaneously Monthly or Quarterly for the Preventive Treatment of Migraine in Adult Chinese Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-09-30","primaryCompletion":"2024-01-31","completion":"2024-06-13","firstPosted":"2022-07-14","resultsPosted":"2025-01-31","lastUpdate":"2025-01-31"},"enrollment":365,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine"],"interventions":[{"type":"DRUG","name":"Fremanezumab","otherNames":["TEV-48125","Ajovy"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Fremanezumab Monthly","type":"EXPERIMENTAL"},{"label":"Fremanezumab Quarterly","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Primary Objective:\n\nTo demonstrate the efficacy of fremanezumab administered as monthly and quarterly subcutaneous (sc) injections to adult Chinese participants with migraine.\n\nSecondary Objectives:\n\n* To further demonstrate the efficacy of fremanezumab administered as monthly and quarterly sc injections.\n* To evaluate the safety and tolerability of fremanezumab administered as monthly and quarterly sc injections.","primaryOutcome":{"measure":"Double Blind (DB) Period: Mean Change From Baseline in Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Fremanezumab","timeFrame":"Baseline (Day -28 to Day -1), up to Week 12","effectByArm":[{"arm":"Placebo","deltaMin":-2.8,"sd":0.48},{"arm":"Fremanezumab Monthly/Quarterly","deltaMin":-4.6,"sd":0.48}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":10},"locations":{"siteCount":29,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":183},"commonTop":["Upper respiratory tract infection","Injection site swelling","Injection site erythema","Injection site pruritus","Hyperlipidaemia"]}}